Introduction {#S0001}
============

Epithelial ovarian cancer is the fourth leading cause of cancer-related death in women in the United States and the leading cause of gynaecological cancer death \[[@CIT0001], [@CIT0002]\]. Due to late-onset symptoms, ovarian cancer is mainly diagnosed in an advanced stage and is therefore associated with poor survival \[[@CIT0003]\]. Complete cytoreduction is the single most important prognostic factor for outcome in patients in whom median overall survival reaches 99.1 months \[[@CIT0004]--[@CIT0006]\]. In order to achieve these results patients need to be treated in specialised gynaeco-oncological centres. However, there is no objective test, evaluating outcome of surgery. Additionally, monitoring of standard systemic therapy with carboplatin and paclitaxel remains unsatisfactory in some cases.

Zhang *et al*. initially described leptin in 1994 \[[@CIT0007]\]. It is a product of obesity gene (ob) and is synthesised mainly by white adipose tissue. Nevertheless its expression was detected in other tissues like placenta or cancer cells. Leptin exists in two forms: free and bound, where the free fraction is the active one. It acts as a negative feedback signal critical to normal control of food intake and body weight. Moreover, anti-apoptotic activity in human cells has been reported. Concomitantly to leptin, expression of different isoforms of its receptors was observed in the studied tissues. Para as well as autocrine action pathway of leptin in carcinogenesis remain possible \[[@CIT0007], [@CIT0008]\].

The available data on leptin serum concentrations in ovarian cancer patients present contradictory results. Tessitore *et al*. \[[@CIT0009]\] reported higher leptin concentration in ovarian cancer patients. Nevertheless, in most available publications lower leptin concentrations in ovarian cancer patients in comparison to healthy individuals were reported \[[@CIT0010]--[@CIT0013]\]. To the authors' knowledge, there are no reports evaluating leptin concentrations during therapy in ovarian cancer patients.

The aim of our study was to evaluate serum leptin levels in ovarian cancer patients before and after primary surgery as well as after first-line chemotherapy. Furthermore, correlations between leptin and CA125, BMI, and FIGO (International Federation of Gynaecology and Obstetrics) stage and grade were analysed.

Material and methods {#S0002}
====================

Patients with primary epithelial ovarian cancer treated at the Department of Oncology, Division of Gynaecology, Poznan University of Medical Sciences were enrolled in our single-centre study.

Patients with suspicious ovarian tumours referred to our centre received frozen section examination during primary surgery. In cases with histologically confirmed epithelial ovarian cancer, enrolment was limited to patients who underwent diagnostic procedures (e.g. paracentesis) only. Furthermore, any women with non-epithelial ovarian neoplasms, recurrent disease, other malignancies, and those who received neoadjuvant chemotherapy were disqualified from this study. The control group consisted of patients with benign ovarian findings.

Gynaecological examination, vaginal ultrasound, and additional radiological imaging were standard diagnostic procedures prior to planned surgery. From all patients, weight and height at the time of diagnosis were used to calculate body mass index (BMI).

Informed consent form was obtained from all of the patients in this study, according to the requirements of the Poznan University of Medical Sciences Bioethics Committee.

Fasting serum samples for antibody microarray analysis were prospectively collected from individuals with primary ovarian cancer and from patients with benign ovarian findings. Blood samples were collected three times: at the time of diagnosis, between days 7 and 10 after primary surgery, and during the fourth week after first-line chemotherapy. In a control group, blood samples were taken twice: before and after surgery.

Quantikine Human ELISA assay kits for each of the analytes selected for further analysis were purchased from R&D Systems. Standard laboratory assay for CA125 concentrations evaluation was used.

Optimal surgery was defined as complete tumour resection and suboptimal as any visible disease residuals. Standard adjuvant chemotherapy consisted of 6 cycles of paclitaxel 175 mg/m^2^ and carboplatin AUC5 or cisplatin 75 mg/m^2^ every three weeks.

Statistical analysis was performed using StatSoft Statistica 6.0. Changes of leptin and CA125 concentrations were evaluated using Student *t*-test. Correlation between BMI, FIGO stage, grade, and leptin concentrations were evaluated using Spearman test.

Results {#S0003}
=======

Fifty-three patients with primary epithelial ovarian cancer treated at the Department of Oncology, Division of Gynaecology, Poznan University of Medical Sciences between 2006 and 2007 met the inclusion criteria and were included in our study. Fifty-one women with benign ovarian tumours were included in the control group.

The average age in the control group was 42.5 years (range 29--68), whereas the average age of women in the study group was 53.9 years (range 44--71). All patients were in good performance status ECOG (Eastern Cooperative Oncology Group) 0 or 1.

Fifteen (29%) women in study group had stage FIGO I/II and 38 (71%) women had stage FIGO III/IV ovarian cancer. The majority of patients had serous pathology -- 39 (73%), followed by mucinous -- 7 (13%), clear cell -- 3 (6%), undifferentiated -- 2 (4%), and endometrioid -- 2 (4%). The grade was determined in 49 patients, among those 10 (21%) had G1, 19 (38%) had G2, and 20 (41%) had G3.

Thirty-three (63%) patients in the study group underwent optimal primary surgery with complete tumour resection. Among those, all 15 (100%) women had early ovarian cancer FIGO I/II and 18 (47%) patients had advanced ovarian cancer FIGO III.

We observed significantly lower mean serum leptin concentrations in ovarian cancer patients vs. control group, 9.26 ±4.04 ng/ml and 15.25 ±2.82 ng/ml (*p* \< 0.0001), respectively ([Fig. 1](#F0001){ref-type="fig"}). Patients with advanced ovarian cancer FIGO III/IV had lower mean serum leptin levels in comparison to women with FIGO I/II stage, 7.08 ±1.87 ng/ml and 14.73 ±1.87 ng/ml, respectively (*p* \< 0.0001) ([Fig. 2](#F0002){ref-type="fig"}). No significant differences in mean serum leptin concentrations were observed between patients with early ovarian cancer and the control group. We did not find any correlation between histology or grade and mean serum leptin levels in our study.

![Mean pre-operative leptin concentrations in ovarian cancer patients (OC) and control group](WO-18-23792-g001){#F0001}

![Mean pre-operative serum leptin concentrations in early FIGO I/II and advanced FIGO III/IV ovarian cancer (OC) patients](WO-18-23792-g002){#F0002}

Subsequently, postoperative mean leptin concentrations were evaluated. No significant differences between pre- and post-operative mean serum leptin levels in study and control group were identified, 11.04 ±4.03 ng/ml (*p* = 0.052) and 14.9 ±3.1 ng/ml (*p* = 0.064) respectively ([Fig. 3](#F0003){ref-type="fig"}). The subgroup analysis showed no significant change of post-operative mean serum leptin concentration in stage FIGO I/II ovarian cancer patients (*p* = 0.057). However, comparison of mean pre- and post-operative leptin concentrations in advanced (FIGO III/IV) ovarian cancer according to performed surgery. Significant elevation to 13.71 ng/ml (*p* \< 0.001) of mean post-operative serum leptin concentrations in patients who underwent complete tumour resection were identified. In contrast, mean post-operative serum leptin levels did not significantly change in patients who underwent suboptimal surgery (*p* = 0.059) ([Fig. 4](#F0004){ref-type="fig"}).

![Pre- and post-operative serum leptin concentrations in ovarian cancer (OC) patients and control group](WO-18-23792-g003){#F0003}

![Mean pre- and post-operative serum leptin concentrations regarding performed surgery and ovarian cancer stage](WO-18-23792-g004){#F0004}

Standard first-line chemotherapy was applied to 52 patients in the study group. One patient diagnosed with ovarian cancer FIGO IA G1 did not receive any adjuvant chemotherapy. 94% of analysed patients received 6 cycles of chemotherapy and the mean number of cycles was 5.8. Significantly higher mean serum leptin concentrations were observed after chemotherapy in comparison to mean post-operative values -- 14.82 ± 4.30ng/ml (*p* \< 0.001). Strong statistically significant elevation of mean serum leptin concentration in patients who underwent suboptimal cytoreduction was identified in advanced ovarian cancer patients, 14.65 ± 2.45ng/ml (*p* \< 0.001). No significant difference was observed in mean serum leptin level after chemotherapy, 14.84 ± 1.95ng/ml (*p* = 0.054), in early ovarian cancer patients in comparison to post-operative mean concentration ([Fig. 5](#F0005){ref-type="fig"}).

![Comparison of mean serum leptin concentrations before and after first-line chemotherapy](WO-18-23792-g005){#F0005}

Mean body mass index (BMI) of patients in the study group was 24 kg/m^2^ (range 18.2--32.8) and 22 kg/m^2^ (range 17.2--30.3) in the control group (*p* \> 0.05). Mean BMI in patients with early ovarian cancer was 23.7 kg/m^2^ (range 18.2--31.9) and in the advanced group 24.4 kg/m^2^ (range 19.0--32.8) (*p* \> 0.05). No statistical difference in initial BMI between early, advanced ovarian cancer, and the control group was found (*p* \> 0.05). We observed positive correlation between serum leptin concentrations and BMI in the control group as well as in early and advanced ovarian cancer patients (*p* \< 0.05). However, mean serum leptin concentrations in women with benign ovarian tumours and early ovarian cancer patients (FIGO I/II) were significantly higher in comparison to advanced ovarian cancer patients (FIGO III/IV) by similar BMI values in those groups (*p* \< 0.05).

Additionally, serum CA125 concentrations in the study group were evaluated. Independently of FIGO stage or surgery, an 86.6% decrease in post-operative mean serum CA125 level (*p* \< 0.001) was found. The decrease of mean serum CA125 concentration was significantly higher in patients who underwent complete cytoreduction versus sub-optimally operated patients, 92% (58.8 U/ml) and 82% (315.2 U/ml) (*p* \< 0.05), respectively. After first-line chemotherapy in patients with advanced disease FIGO III/IV who underwent complete surgery, mean serum CA125 levels decreased to 28.1 U/ml (53.2% decrease) and 34.1 U/ml (89.2% decrease) in women who received suboptimal cytoreduction in comparison to post-operative levels.

Discussion {#S0004}
==========

The majority of available publications show low serum leptin concentrations in ovarian cancer patients at the time of diagnosis \[[@CIT0010]--[@CIT0013]\]. Mor *et al*. published data of 100 ovarian cancer patients, including 24 FIGO stage I/II cases, in comparison to women with benign adnexal findings \[[@CIT0010]\]. Further investigation by Visintin *et al*. showed analogical results from 156 women with ovarian malignancies \[[@CIT0011]\]. Moreover, these authors reported differences according to stage of disease. Patients with advanced stage disease FIGO III/IV had significantly lower serum leptin levels in comparison to FIGO I/II cases. The results of our research correspond with the above-mentioned studies. Data presented by Mor *et al*. and Visintin *et al*., as well as our investigation, are based on the highest number of enrolled patients and presumably reflect the real situation. According to these observations, leptin might be considered as a potential factor in preoperative ovarian-mass diagnostics.

Our study showed statistically significant elevation of serum leptin concentrations after complete cytoreduction in advanced ovarian cancer patients. This correlation was not observed in patients who underwent suboptimal surgery or those with early ovarian cancer. To the authors' knowledge, our study is the first research showing differences in initial and post-operative serum leptin levels. A large number of patients with advanced ovarian cancer present ascites at the time of diagnosis. Abramov et al. reported post-operative elevation of initially low serum leptin concentrations in a patient with Meigs syndrome after removal of ascites \[[@CIT0014]\]. Another study showed low leptin levels in patients with androgen-secreting ovarian tumour and its post-operative normalisation without parallel BMI or fat tissue distribution changes \[[@CIT0015]\]. The above data may suggest a direct association of low serum leptin concentrations with initial tumour burden and/or the presence of ascites. Leptin production depends mainly on body weight, which in our study positively correlated with the BMI of patients. However, we did not find differences in BMI between advanced, early ovarian cancer, and the control group. Barber *et al*. reported higher resting energy expenditure due to tumour load despite weight loss \[[@CIT0016]\]. Concomitant cancer progression, inflammation, and catabolic processes lead to decrease of serum leptin concentration. Increased energy output induced by tumour growth results in lower leptin production and therefore decreased metabolism and food intake. Nevertheless these processes resulting in decreased leptin serum concentrations begin before loss of weigh appears \[[@CIT0017]--[@CIT0020]\]. Several studies showed elevated leptin concentrations associated with cancer risk when its serum levels were measured prospectively \[[@CIT0021], [@CIT0022]\]. Elevated or normal leptin concentrations were reported in analyses of patients performed 1.5 years before diagnosis for colorectal \[[@CIT0022]\] and breast cancer \[[@CIT0022]\], respectively. However, leptin levels measured at the time of diagnosis in patients with gastrointestinal and other cancers are lower in comparison to control groups \[[@CIT0023], [@CIT0024]\]. Therefore, the timing of blood collection in relation to disease onset might significantly affect leptin concentrations. Subsequently, complete removal of the tumour, and therefore normalisation of metabolic processes, might lead to leptin levels elevation. Summarising, the comparison of pre- and post-operative leptin concentrations might be useful in the evaluation of cytoreduction completeness. However, the influence of other factors should not be underestimated and needs further investigation.

A decrease in post-operative serum CA125 levels was also observed in our patients. The change in its concentration was found to be independent in regard to performed surgery. However, in patients who underwent complete cytoreduction, the decrease in post-operative values was significantly greater in comparison to that seen in women who received suboptimal surgery. Furthermore, the latter subgroup of patients presented significantly higher initial CA125 values. Yedema *et al*. showed post-operative decrease in CA125 in only a minority of investigated patients, concluding the limited role of CA125 in the evaluation of residual tumours \[[@CIT0025]\]. Mogensen *et al*. reported limited significance of post-operative CA125 levels due to other perioperative factors besides residual disease influencing its concentrations \[[@CIT0026]\]. Nevertheless, in 1996 Gaducci *et al*. presented differences of pre- and post-operative CA125 levels according to the size of residual tumours \[[@CIT0027]\]. The post-operative decline of CA125 concentrations was significantly higher in patients with smaller residual disease. This observation is in accordance with our study. CA125 in combination with serum leptin levels might serve as a potential marker for cytoreduction completeness monitoring.

Subsequently we analysed leptin concentrations in patients after chemotherapy. According to the findings of the first part of our study, the differences in serum leptin levels varied according to the stage of disease. Highly significant elevation of serum leptin concentrations have been observed in patients with advanced ovarian cancer FIGO III/IV, who underwent suboptimal primary surgery. In those patients with high postoperative tumour burden, remission achieved due to given chemotherapy resulted in normalisation of leptin concentrations. Comparison to an established ovarian cancer marker CA125 showed a negative correlation between its declining levels and rising leptin concentrations during the chemotherapy. Again, normalisation of leptin levels after completion of therapy might suggest that tumour burden and therefore altered metabolism is responsible for its initial lower concentrations in advanced ovarian cancer cases FIGO III/IV. Nevertheless, the exact mechanism of leptin serum elevation remains unclear and needs further investigation.

Analogically to other authors, we have observed a positive correlation between leptin concentrations and BMI in our patients \[[@CIT0028]\]. However, leptin levels in patients with advanced ovarian cancer were significantly lower in comparison to early ovarian cancer cases and the control group, despite similar mean BMI values. This observation suggests a limited influence of BMI on leptin levels in cancer patients. Association of initially low serum leptin levels with tumour burden or presence of ascites in those cases remains very probable.

The primary complete cytoreduction in ovarian cancer patients remain mainstay in successful treatment of this disease \[[@CIT0004]--[@CIT0006]\]. Our study is the first prospective investigation showing differences of serum leptin concentrations in primary ovarian cancer patients during the therapy. Evaluation of pre- and post-operative leptin serum concentrations might be a potential objective tool for surgery completeness monitoring. Moreover, complementary to CA125, it could play a role in chemotherapy response evaluation. Nevertheless, in our opinion further investigations on larger groups of patients remain necessary.

The Polish Committee for Scientific Research N N407 3475 33 supported this study.


Donald Trump on Thursday sought to discredit the women who have accused him of groping and lashed out at the news organizations that have printed their stories, as the GOP nominee seeks to beat back cascading stories about alleged his sexual misconduct toward women.

Speaking from a teleprompter at a rally in West Palm Beach, Fla., Trump ripped his accusers, calling their stories “slander and libel” and part of a “concerted, coordinated and vicious attack” launched by Hillary Clinton Hillary Diane Rodham ClintonButtigieg stands in as Pence for Harris's debate practice Senate GOP sees early Supreme Court vote as political booster shot Poll: 51 percent of voters want to abolish the electoral college MORE and the news media to take down his campaign.

ADVERTISEMENT

Trump said he has “substantial evidence” that the women’s claims are false and vowed to release his findings sometime “very soon.”

“Their claims are preposterous, ludicrous and defy logic,” Trump said.

“These lies come from outlets whose past stories and claims have already been discredited,” he added. “The media outlets did not attempt to confirm the most basic facts because even a simple investigation would have shown these were nothing more than false smears.”

Trump hurled insults at the press, describing it as an entrenched establishment force “in bed” with the Hillary Clinton and hell-bent on getting her elected president.

He called the news media “the most powerful weapon” in the Clinton arsenal and accused reporters of “conspiring directly” with his rival to ensure she wins the White House.

“Their agenda is to elect Crooked Hillary Clinton at any cost, any price, no matter how many lives they destroy,” he said. “For them, it is war.”

“They will attack you and slander you and seek to destroy your career and family and everything about you, including your reputation,” Trump added. “They will lie, lie, lie and do worse than that. Whatever is necessary.”

Over the last 24 hours, multiple women have come forward to accuse Trump of uninvited kissing or groping.

In reports and first-person accounts recorded in The New York Times, People magazine and The Palm Beach Post, four women have accused Trump of forcibly kissing them or aggressively touching them against their will.

Trump said Thursday that his lawyers are preparing a defamation suit against the New York Times as part of an offensive meant to push back on the claims.

The newspaper, Trump said, had suffered an “embarrassment” when a previous story – authored by the same two reporters – had fallen apart earlier this year.

“The same two discredited reporters who should have been fired tell another fabricated and false story that supposedly took place,” Trump said. “Another ridiculous tale.”

Several women in a New York Times story about Trump’s mistreatment of women released earlier this year later said they were misquoted or taken out of context and that they support and admire Trump.

The paper shot back in a statement:

“We published newsworthy information about a subject of deep concern,” the paper said. “If Mr. Trump disagrees, if he believes that American citizens had no right to hear what these women had to say and that the law of this country forces us and those who would dare criticize him to stand silent or be punished, we welcome the opportunity to set him straight in court.”

The women came forward after Trump at Sunday's debate denied making unwanted sexual advances toward women, an issue raised after he was caught on a hot microphone bragging about kissing and grabbing women, and talking about how he can get away with it because he’s a celebrity.

Trump has dismissed the comments as “locker room talk” and has denied that he ever behaved in that way.

At the Thursday rally, Trump addressed the specific claims against him and said the allegations would not withstand further scrutiny.

“These vicious claims about me of inappropriate conduct with women are totally and absolutely false,” Trump said. “These claims are all fabricated, they’re pure fiction and outright lies. These events never happened and the people who said them meekly understand.”

Trump addressed the specific claims against him one-by-one, giving his view of why the allegations would not withstand scrutiny.

People magazine published a first-person story on Wednesday night by one of its former writers, who said she had received unwanted advances from Trump in December 2005 while she toured Trump’s Mar-a-Lago resort for an interview with Trump and his wife.

After a pregnant Melania Trump left her alone with Donald Trump Donald John TrumpOmar fires back at Trump over rally remarks: 'This is my country' Pelosi: Trump hurrying to fill SCOTUS seat so he can repeal ObamaCare Trump mocks Biden appearance, mask use ahead of first debate MORE, writer Natasha Stoynoff said, Trump pushed her against a wall and forcibly kissed her.

Trump said that an eyewitness has debunked the story, although he did not say who. He claimed the encounter took place in a room full of windows that anyone could look into.

And the story that ran in People at the time was a glowing piece about his marriage, Trump said.

The GOP nominee asked why the reporter did not write about how a huge television celebrity had assaulted her, which would have been a much bigger story, he said.

“Why wasn’t it part of the story that appeared 12 years ago?,” Trump asked. “Why didn’t they make it part of the story?..It would have been one of the biggest stories of the years.”

“It would have been the headline,” Trump continued. “These are horrible people, horrible liars, and it happens to appear 26 days before our very important election.”

Trump also shot back at Jessica Leeds, now 74, who told the Times that Trump had groped her while seated on a flight in the 1980s. She said that Trump began to grab her breasts and tried to put his hand up her skirt as he sat next to her, the two strangers until the interaction.

“He was like an octopus ... his hands were everywhere,” she told The Times.

“It was an assault.”

Trump questioned why there were no witnesses to that event, which allegedly took place on an airplane more than 30 years ago.

He did not address another woman in the same story, Rachel Crooks, who told the Times that Trump kissed her on the month when she was a 22-year-old receptionist in 2005, or a report from the Palm Beach Post that Trump had groped a woman at a resort near Miami in 2003.

As Trump spoke, First Lady Michelle Obama had just finished her own speech in Manchester, N.H., ripping the GOP nominee for his treatment of women and defending Hillary Clinton’s marriage against Trump’s attacks.

“This is not normal, this is not politics as usual,” Obama said. “This is disgraceful, it is intolerable.”

“We simply cannot endure this or expose our children to this any longer,” she said. “Now is the time for us all of us to stand up and say, ‘enough is enough.’ This has got to stop right now.”


Targeted capture and sequencing of gene-sized DNA molecules.
Targeted capture provides an efficient and sensitive means for sequencing specific genomic regions in a high-throughput manner. To date, this method has mostly been used to capture exons from the genome (the exome) using short insert libraries and short-read sequencing technology, enabling the identification of genetic variants or new members of large gene families. Sequencing larger molecules results in the capture of whole genes, including intronic and intergenic sequences that are typically more polymorphic and allow the resolution of the gene structure of homologous genes, which are often clustered together on the chromosome. Here, we describe an improved method for the capture and single-molecule sequencing of DNA molecules as large as 7 kb by means of size selection and optimized PCR conditions. Our approach can be used to capture, sequence, and distinguish between similar members of the NB-LRR gene family-key genes in plant immune systems.


MakerCon was developed for Makers like Erin Tomson, someone who has an idea to make something better and wants to learn the process of taking that idea and developing into a product that creates value for the Maker community. As Erin tells us below, she came to MakerCon last year and it got on her track for launching this week her new product on Kickstarter. – Dale Dougherty, founder and Executive Chairman of Maker Media

Like many Makers, I’ve been interested in electronics since I was a kid. At that time, building electronics often meant paging through datasheets and stringing together individual logic ICs on a breadboard. Microcontrollers were available, but they weren’t nearly as easy to use as they are today. Even once a circuit worked, taking it from a breadboard to a finished project was a drawn out and difficult process.

After college I took a job at Pixar as a technical director. I threw myself into computer graphics, working on Finding Nemo, The Incredibles, and Ratatouille before moving over to Pixar’s internal software group. There I helped to build Pixar’s next generation animation tools from the ground up.

A couple years ago I started getting back into electronics again as a hobby. In doing so I became very aware of what had changed since I was younger. The landscape had been totally transformed by inexpensive, easy to use microcontrollers like Arduino and single board computers like Raspberry Pi. Where the behavior of an electronics project used to be painstakingly created with chips and wires, it could now be defined quickly and easily with a few lines of code.

Other things haven’t changed since I was a kid, and I found that even more interesting. Just like back then, most electronics projects are strung together on breadboards, a process that’s fragile and complicated. Though microcontrollers make it easier to control a project, careful attention must still be paid to mundane details like pinouts and supply voltages.

The difficulty of connecting components together stood in stark contrast to the power and flexibility of modern programmable electronics. After thinking about the problem for a while, I felt like I could apply what I had learned about building software for artists and animators at Pixar to make electronics easier for everyone. I quit my job at Pixar and started working on a solution to this problem.

At that point I was working alone and feeling pretty intimidated by the process of starting and launching a business. Last year, I attended MakerCon for some fresh inspiration and it was a really great experience. Sessions at MakerCon covered all the things I was trying to get my head around, like how to approach manufacturing and the ins and outs of crowdfunding. I also met some really great contacts and got a peek into what other professional Makers were doing.

Reinvigorated, I got back to work and was soon making steady progress. I call the system I’ve come up with Modulo, and today I’m launching it on KickStarter!

Modulo is a simple solution for building powerful electronic devices. Modulos are small interchangeable components that slide into a base which holds them firmly and connects them together. It can be programmed using the Arduino IDE or controlled from Python running on a computer or Raspberry Pi. With Modulo, I think I’ve addressed many of the difficulties that make building electronics so complicated and cumbersome.

As far as the specific Modulos themselves, I’m starting with versatile favorites like a microcontroller, an illuminated push button knob, and a color OLED display. Over time I plan to create a wide range of different Modulos that do all sorts of different things.

I chose to pursue this project partly because of the incredible Maker community. It’s so amazing to see people focused on what they can contribute and how we can all build each other up. I hope that Modulo can be my contribution and I can’t wait to see what people create with it.

Modulo is on KickStarter now, so please check out the KickStarter page and consider backing it to help me get it off the ground!